May 1, 2018 / 11:10 AM / 23 days ago

BRIEF-Vivus Expands Its Commercial Product Portfolio With The Acquisition Of Pancreaze

May 1 (Reuters) - Vivus Inc:

* VIVUS EXPANDS ITS COMMERCIAL PRODUCT PORTFOLIO WITH THE ACQUISITION OF PANCREAZE®

* VIVUS - ENTERED INTO AGREEMENT TO BUY ALL PRODUCT RIGHTS FOR PANCREAZE (PANCRELIPASE) DELAYED-RELEASE CAPSULES IN U.S. & CANADA HELD BY JANSSEN PHARMA

* VIVUS INC - UPON CLOSING, VIVUS WILL ACQUIRE PANCREAZE FROM JANSSEN FOR $135 MILLION. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below